Summit plunges 80 pct after muscle-wasting disorder drug fails

(Reuters) - Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed a mid-stage study, wiping out nearly 80 percent of its market value.